With Catherine Jacobson, the quest to examine, understand and exploit the potential of cannabis is personal as well as professional.

Her young son, Ben, was born with a severe form of epilepsy. She exhausted virtually every form of federally-approved treatment before discovering evidence for the seizure-inhibiting potential of cannabidiol (CBD, which, along tetrahydrocannabinol–THC–is the most prevalent cannabinoid in the cannabis plant). A short time after adding CBD to Ben’s treatment regime, the frequency of his seizures diminished by 40%.

This discovery changed the course of her career, drawing her to specialize in an underdeveloped field of study–medical cannabis–that may have the potential to help thousands of children. That pathway eventually led Dr. Jacobson to become Tilray’s Director of Clinical Research.

A neuroscientist, Dr. Jacobson is wholly dedicated to standard, proven methods to determine the efficacy and safety of substances that may have medicinal value. Through her position at Tilray, she brings her passion, dedication and expertise to forge partnerships with physicians and medical research institutions worldwide. She was instrumental in the collaborative process of developing Tilray’s liquid cannabis extracts, which greatly facilitate the research process by providing precise, consistent concentrations of active ingredients. Only in this way can accurate evaluations of efficacy, dosages and safety be determined in clinical testing, thus ensuring maximum benefits for patients.

catherine-interview-copy She closely monitors and–when possible–facilitates global research, which at this time includes a growing number of illnesses in addition to epilepsy, such as PTSD, arthritic pain and nausea and vomiting caused by chemotherapy.

A featured speaker at international medical conferences, Dr. Jacobson has authored numerous articles in prominent publications such as the National Post and The Guardian and appeared on the US’ Public Broadcasting Service.